Health Catalyst (HCAT) Scheduled to Post Earnings on Wednesday

Health Catalyst (NASDAQ:HCAT) is set to issue its quarterly earnings data after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of $0.10 per share for the quarter. Health Catalyst has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Individual that wish to register for the company’s earnings conference call can do so using this link.

Health Catalyst (NASDAQ:HCAT) last announced its earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.04. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. The company had revenue of $75.90 million during the quarter, compared to analysts’ expectations of $74.96 million. During the same quarter in the previous year, the business posted ($0.21) earnings per share. Health Catalyst’s quarterly revenue was up 3.7% on a year-over-year basis. On average, analysts expect Health Catalyst to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Health Catalyst Stock Performance

NASDAQ:HCAT opened at $7.70 on Monday. Health Catalyst has a 52 week low of $5.42 and a 52 week high of $11.41. The firm’s 50-day simple moving average is $7.95 and its 200 day simple moving average is $7.07. The firm has a market cap of $465.62 million, a price-to-earnings ratio of -5.13 and a beta of 1.32.

Insider Buying and Selling at Health Catalyst

In other news, COO Daniel Lesueur sold 8,137 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total value of $61,678.46. Following the sale, the chief operating officer now owns 140,108 shares of the company’s stock, valued at $1,062,018.64. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total transaction of $54,150.00. Following the sale, the insider now owns 255,881 shares of the company’s stock, valued at approximately $1,847,460.82. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Daniel Lesueur sold 8,137 shares of the stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total transaction of $61,678.46. Following the completion of the sale, the chief operating officer now directly owns 140,108 shares in the company, valued at approximately $1,062,018.64. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,187 shares of company stock valued at $226,171 over the last three months. 2.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several brokerages recently commented on HCAT. Stephens dropped their price objective on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a research note on Thursday, August 8th. JPMorgan Chase & Co. lifted their price objective on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Piper Sandler cut their price target on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a report on Monday, August 26th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a report on Friday, October 4th. Finally, Evercore ISI lifted their price target on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.90.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.